Lakefront Biotherapeutics Sponsored ADR (LKFT:NASDAQ) closed at $29.79 on October 19, 2026, down 0.37% on the day. The stock trades 17.8% below its 52-week high of $36.24 and 16.0% above its 52-week low of $25.68. Over the past year, it lost 3.2%. Lakefront Biotherapeutics Sponsored ADR is part of the Health Care sector.
In 230 trading sessions since November 18, 2025, LKFT closed higher on 112 days (49%). Its best day was August 11, 2026 (+6.76%) and its worst was March 24, 2026 (-6.58%). It never moved 10% or more in a single session.
Galapagos (to be renamed Lakefront Biotherapeutics as of May 8, 2026) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Find more stocks like LKFT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.